
We aimed to compare clinical outcomes with anti‐PD(L)1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation (RT) prior to developing metastatic disease. Prior RS prior to developing advanced disease was associated with better outcomes in patients with aUC treated with ICI in the 2nd+, but not in the 1st line setting.
Like
Save
Share